Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors
Amanda M. Haidet(Nationwide Children's Hospital), Brian K. Kaspar(Nationwide Children's Hospital), Zarife Sahenk(The Ohio State University), Daniel R. Boué(Nationwide Children's Hospital), Liza Rizo(Nationwide Children's Hospital), Paul T. Martin(Nationwide Children's Hospital), Jerry R. Mendell(Nationwide Children's Hospital), Chalonda R. Handy(Nationwide Children's Hospital), Amy Eagle(Nationwide Children's Hospital), Chris Shilling(Nationwide Children's Hospital), Priya Umapathi(Nationwide Children's Hospital)
Cited by 261
Related Papers
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522